Biotechnology Acquisitions in Indiana

Eli Lilly and Company completed the acquisition of POINT Biopharma Global Inc. after a tender offer at $12.50 per share in cash, followed by a second-step merger and delisting of POINT's common stock. The transaction brings POINT's radioligand therapy pipeline and radiopharmaceutical capabilities into Lilly's oncology research and development efforts.

Cortexyme, Inc. (Nasdaq: CRTX) has acquired privately-held Novosteo, adding Novosteo's bone-targeting therapeutic platform and lead candidate NOV004 to Cortexyme's pipeline. The deal (now closed) gives Novosteo stockholders ~15.5% of the combined company and will see Cortexyme operate under the new name Quince Therapeutics with Novosteo executives joining the leadership team.

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.